Appili Therapeutics Inc. (TSX:APLI)
Canada · Delayed Price · Currency is CAD 0.0100
0.00 (0.00%)
Sep 3, 2026, 4:10 PM EST
Appili Therapeutics Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 0.36 | 0.24 | 0.1 | 0.83 | 0.33 | 1.39 | |
Revenue Growth | 260.48% | 143.10% | -87.86% | 147.59% | -75.97% | - |
Gross Profit | 0.36 | 0.24 | 0.1 | 0.83 | 0.33 | 1.39 |
Selling, General & Admin | 2.87 | 2.48 | 2.86 | 3.26 | 4.62 | 5.32 |
Research & Development | 4.03 | 4.29 | 7.32 | 5.62 | 3.62 | 20.74 |
Operating Expenses | 6.9 | 6.77 | 10.19 | 8.88 | 8.25 | 26.07 |
Operating Income | -6.54 | -6.52 | -10.09 | -8.05 | -7.91 | -24.68 |
Interest Expense | -1.48 | -1.72 | -2.95 | -1.63 | -0.95 | -1.55 |
Interest & Investment Income | - | - | 0 | 0.02 | 0.03 | 0.03 |
Currency Exchange Gain (Loss) | -0.3 | 0.21 | -0.33 | 0.07 | -0.36 | 0.06 |
Other Non Operating Income (Expenses) | 3.71 | 3.89 | 10.76 | 5.89 | 0.14 | 1.06 |
EBT Excluding Unusual Items | -4.61 | -4.14 | -2.61 | -3.71 | -9.06 | -25.08 |
Other Unusual Items | - | - | - | - | -0.14 | - |
Pretax Income | -4.61 | -4.14 | -2.61 | -3.71 | -9.21 | -25.08 |
Income Tax Expense | 0.08 | 0.11 | 0.02 | 0.07 | 0.04 | 0.04 |
Net Income | -4.69 | -4.24 | -2.62 | -3.78 | -9.24 | -25.12 |
Net Income to Common | -4.69 | -4.24 | -2.62 | -3.78 | -9.24 | -25.12 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 126 | 124 | 121 | 121 | 114 | 67 |
Shares Outstanding (Diluted) | 126 | 124 | 121 | 121 | 114 | 67 |
Shares Change | 4.31% | 2.02% | - | 6.63% | 70.43% | 12.76% |
EPS (Basic) | -0.04 | -0.03 | -0.02 | -0.03 | -0.08 | -0.38 |
EPS (Diluted) | -0.04 | -0.03 | -0.02 | -0.03 | -0.08 | -0.38 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -1.37 | -1.34 | 0.87 | -2.49 | -10.1 | -19.08 |
Free Cash Flow Per Share | -0.01 | -0.01 | 0.01 | -0.02 | -0.09 | -0.29 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -1804.94% | -2672.16% | -10040.58% | -972.94% | -2368.29% | -1774.56% |
Profit Margin | -1295.49% | -1736.73% | -2613.12% | -456.96% | -2765.90% | -1806.18% |
Free Cash Flow Margin | -377.83% | -547.72% | 862.63% | -301.44% | -3022.65% | -1372.07% |
EBITDA | -6.53 | -6.52 | -10.07 | -8.04 | -7.91 | -24.67 |
D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
EBIT | -6.54 | -6.52 | -10.09 | -8.05 | -7.91 | -24.68 |
Revenue as Reported | 0.36 | 0.24 | 0.1 | 0.84 | 0.36 | 1.42 |